**S9 Table.** **Adverse drug events for BMT patients**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Year 1** | **Year 2** | **Year 3** | **Year 4** | **Year 5** | **Deterministic sensitivity analysis** | **Probabilistic sensitivity analysis distribution** |
| Oedema Risk (%) | 0 | 0 | 0 | 0 | 0 | Fixed | Fixed |
| Hypoglycemia Risk (%) | 2.43 | 0 | 0 | 0 | 0 | +/-20% | Beta |
| Hip Fracture Risk (%) | 0 | 0 | 0 | 0 | 0 | Fixed | Fixed |
| Non-Compliance Risk (%)\* | 0 | 0 | 0 | 0 | 0 | Fixed | Fixed |
| Weight gain (kg) | 0 | 0 | 0 | 0 | 0 | Fixed | Fixed |
| Deterioration in TC: HDL (%) | -3.47 | 0 | -1.81 | 0 | 0 | Fixed | Fixed |

\* % of patients with reduced drug dose and increase in HbA1c. TC:HDL (total cholesterol: high-density lipoproteins)